OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	11/18/2004 8:51:42 PM
	Read Replies (1) of 447

Congrat to OSIP holders. Surprise is second line settings, so we need to se full label. FDA Approves Tarceva-TM- For Patients with Advanced Non-Small Cell Lung Cancer Thursday November 18, 7:17 pm ET Only Targeted EGFR Therapy Shown to Improve Survival in Advanced Non-Small Cell Lung Cancer MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 18, 2004--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - News) and Genentech, Inc. (NYSE: DNA - News) announced today that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva(TM) (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Tarceva(TM) is an oral tablet indicated for daily administration. Tarceva(TM) is the only drug in the epidermal growth factor receptor (EGFR) class to demonstrate in a Phase III clinical trial an increase in survival in advanced NSCLC patients. Tarceva(TM) will be available within five shipping days.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next